Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.

Abstract

Second-generation antipsychotics (SGAs), valproate, and sulpiride are related to significant weight gain and risk of metabolic syndrome (MetS). Among SGAs, olanzapine and clozapine are associated with the highest metabolic risk while ziprasidone is among one of the SGAs with the lowest risk. Several reports suggest that weight loss is observed in switching other antipsychotics to ziprasidone. Here we describe a female patient with chronic paranoid schizophrenia who had an unexpected weight gain and developed MetS during a cross-switch from a polypharmacy of olanzapine, valproate and sulpiride to ziprasidone monotherapy.

• Authors: Chin-Pang Lee, Alice Pei-Jung Chen, Yeong-Yuh Juang
• Journal: Clinical schizophrenia & related psychoses (Clin Schizophr Relat Psychoses) Vol. 9 Issue 3 Pg. 141-4 ( 2015) ISSN: 1941-2010 [Electronic] United States
• PMID: 23644168 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Piperazines
• Thiazoles
• ziprasidone

Topics

• Adult
• Antipsychotic Agents (adverse effects)
• Female
• Humans
• Metabolic Syndrome (chemically induced)
• Piperazines (adverse effects)
• Polypharmacy
• Schizophrenia, Paranoid (drug therapy)
• Thiazoles (adverse effects)
• Weight Gain (drug effects)